Edward Schuchman

Scientific Advisor / Board Member

Edward serves on the Aceragen scientific advisory board for his breakthrough enzyme and Farber disease research. His team was the first to isolate genes encoding lysosomal enzymes linked to Types A and B Niemann-Pick, Mucopolysaccharidosis Type VI, and Farber disease. Those studies led to the first genetic screening program and clinical trials of enzyme replacement therapy for Type B Niemann-Pick disease, now underway.

More than 150 peer-reviewed research articles on lysosomal enzymes and storage diseases have been published by Edward. As a reviewer for leading scientific journals, he has served on and chaired numerous NIH grant review committees and is a member of several scientific advisory boards.

Edward received his Ph.D. in Human Genetics from the Icahn School of Medicine at Mt Sinai in 1983, and after completing a postdoctoral fellowship at Yale University, returned to the Icahn School of Medicine at Mt. Sinai and has been a faculty member since 1986.